Purdue Pharma LP, a member company for pharmaceutical manufacturers, will present new clinical data on Transcept Pharmaceuticals’ Intermezzo (zolpidem tartrate) sublingual tablet CIV, an FDA-approved drug in the treatment of insomnia.

The results are based on a four-week outpatient trial for insomnia and will discuss potential differences in the effects of the drug, based on gender. The presentation will be titled: “Sex Differences in Middle-of-the-Night Efficacy of Zolpidem Tartrate Sublingual Tablets in a 4-Week Insomnia Outpatient Trial.”

Data will be presented on March 20, 2013, at the 65th Annual Meeting of the American Academy of Neurology in San Diego.

Intermezzo sublingual tablet CIV is approved for treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, but only if the patient has at least four hours of bedtime remaining, according to the company.

More important safety information on the drug can be found on Purdue Pharma’s website.